Cargando…

Statins Neuromuscular Adverse Effects

Statins are drugs widely prescribed in high-risk patients for cerebrovascular or cardiovascular diseases and are, usually, safe and well tolerated. However, these drugs sometimes may cause neuromuscular side effects that represent about two-third of all adverse events. Muscle-related adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales: Attardo, Silvia, Musumeci, Olimpia, Velardo, Daniele, Toscano, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369175/
https://www.ncbi.nlm.nih.gov/pubmed/35955495
http://dx.doi.org/10.3390/ijms23158364
_version_ 1784766378812637184
author Attardo, Silvia
Musumeci, Olimpia
Velardo, Daniele
Toscano, Antonio
author_facet Attardo, Silvia
Musumeci, Olimpia
Velardo, Daniele
Toscano, Antonio
author_sort Attardo, Silvia
collection PubMed
description Statins are drugs widely prescribed in high-risk patients for cerebrovascular or cardiovascular diseases and are, usually, safe and well tolerated. However, these drugs sometimes may cause neuromuscular side effects that represent about two-third of all adverse events. Muscle-related adverse events include cramps, myalgia, weakness, immune-mediated necrotizing myopathy and, more rarely, rhabdomyolysis. Moreover, they may lead to peripheral neuropathy and induce or unmask a preexisting neuromuscular junction dysfunction. A clinical follow up of patients assuming statins could reveal early side effects that may cause neuromuscular damage and suggest how to better modulate their use. In fact, statin dechallenge or cessation, or the alternative use of other lipid-lowering agents, can avoid adverse events. This review summarizes the current knowledge on statin-associated neuromuscular adverse effects, diagnosis, and management. It is conceivable that the incidence of neuromuscular complications will increase because, nowadays, use of statins is even more diffused than in the past. On this purpose, it is expected that pharmacogenomic and environmental studies will help to timely predict neuromuscular complications due to statin exposure, leading to a more personalized therapeutic approach.
format Online
Article
Text
id pubmed-9369175
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93691752022-08-12 Statins Neuromuscular Adverse Effects Attardo, Silvia Musumeci, Olimpia Velardo, Daniele Toscano, Antonio Int J Mol Sci Review Statins are drugs widely prescribed in high-risk patients for cerebrovascular or cardiovascular diseases and are, usually, safe and well tolerated. However, these drugs sometimes may cause neuromuscular side effects that represent about two-third of all adverse events. Muscle-related adverse events include cramps, myalgia, weakness, immune-mediated necrotizing myopathy and, more rarely, rhabdomyolysis. Moreover, they may lead to peripheral neuropathy and induce or unmask a preexisting neuromuscular junction dysfunction. A clinical follow up of patients assuming statins could reveal early side effects that may cause neuromuscular damage and suggest how to better modulate their use. In fact, statin dechallenge or cessation, or the alternative use of other lipid-lowering agents, can avoid adverse events. This review summarizes the current knowledge on statin-associated neuromuscular adverse effects, diagnosis, and management. It is conceivable that the incidence of neuromuscular complications will increase because, nowadays, use of statins is even more diffused than in the past. On this purpose, it is expected that pharmacogenomic and environmental studies will help to timely predict neuromuscular complications due to statin exposure, leading to a more personalized therapeutic approach. MDPI 2022-07-28 /pmc/articles/PMC9369175/ /pubmed/35955495 http://dx.doi.org/10.3390/ijms23158364 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Attardo, Silvia
Musumeci, Olimpia
Velardo, Daniele
Toscano, Antonio
Statins Neuromuscular Adverse Effects
title Statins Neuromuscular Adverse Effects
title_full Statins Neuromuscular Adverse Effects
title_fullStr Statins Neuromuscular Adverse Effects
title_full_unstemmed Statins Neuromuscular Adverse Effects
title_short Statins Neuromuscular Adverse Effects
title_sort statins neuromuscular adverse effects
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369175/
https://www.ncbi.nlm.nih.gov/pubmed/35955495
http://dx.doi.org/10.3390/ijms23158364
work_keys_str_mv AT attardosilvia statinsneuromuscularadverseeffects
AT musumeciolimpia statinsneuromuscularadverseeffects
AT velardodaniele statinsneuromuscularadverseeffects
AT toscanoantonio statinsneuromuscularadverseeffects